Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
The 78th World Health Assembly has been a whirlwind week for ADI as, after 18-months of advocacy, the World Health Assembly has agreed to extend the Global Action Plan on the Public Health Response to Dementia by 6-years, to 2031.
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.
Eisai’s lecanemab will represent the second anti-Amyloid Beta therapy to be evaluated by the FDA as a disease modifying treatment for early Alzheimer’s disease.
This report reviews progress towards the implementation of the 7 action areas of the plan by Member States, WHO and civil society, and all those involved in tackling the dementia pandemic.
ADI members in the Middle East region took part in their first regional meeting of 2021 and since the COVID-19 pandemic began in early 2020.
ADI members in the African region took part in their first regional meeting of 2021 and since the COVID-19 pandemic began in early 2020.
The World Alzheimer Report 2020 has been awarded the European Healthcare Design (EHD) 2021 Award for Outstanding Contribution to Global Knowledge.
Aduhelm (aducanumab) is the first new dementia drug treatment to come to market since 2003.
As the 74th World Health Assembly begins, ADI is sharing a statement submitted to the World Health Organization (WHO) and Member States.
ADI members in the European and Caribbean regions took part in the first regional meetings of 2021 and since the COVID-19 pandemic began in early 2020.